We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Renalytix Plc | RENX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.75 | -10.77% | 14.50 | 13:09:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 15.75 | 13.50 | 15.75 | 14.50 | 16.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 11/4/2024 17:30 by 1jat The company has not given any thoughts on margins, but I would compare it with Pharma where product cost is typically 20% and sales/general costs another 30% for an established product….There would be costs anyway in operating the test, so the incremental costs of outsourcing might push the lab cost up by a further 10-20%….should still be profitable…but it does allow scalability which is key to RENX being able to penetrate the addressable market. |
Posted at 09/4/2024 20:24 by f56 OK.I hear what you are saying. How do you think that would translate into profit for RENX if they have to follow that kind of model? |
Posted at 09/4/2024 17:26 by 1jat F56 - how relevant is the invitae case to RENX?I expect RENX has the IP/technology and will licence testing to labs….they certainly dont have the infrastructure to set up labs, lab cost will take a chunk of the $950 tariff for the test. |
Posted at 13/3/2024 14:28 by 1jat I am encouraged the founders/champions of RENX have bought into the fund raise…..but they are the funder of last resort at the moment.The fund raise provides an immediate stay of execution for the company and will allow the sale of business process to proceed without a gun to the directors heads….however they need to recognise that either they will need to sell the business or be prepared to fund the company until it can make itself cash generative. They must hope the continued adoption in clinical standards will result in substantial demand for tests. That is what gives me hope that they can land a decent offer and sell the company. |
Posted at 12/3/2024 09:53 by faz Good to see Howard Doran appointed as Business Manager to drive sales all of six months ago doesnt even list RENX as his employer. Fact he's yet another one in his mid 60s picking up a pension salary here probably means he's forgotten where he works. They know how to pick them |
Posted at 19/12/2023 19:45 by f56 Renx is trying desperately to get to grips with its debt load. It has just issued new shares to pay off existing debt to the tune of 1 million. It is not clear whether new or existing shareholders will benefit in any way from the issue of the new shares. |
Posted at 11/12/2023 19:33 by jonjoalex Looks like it’s game over for RENX ! |
Posted at 14/11/2023 11:20 by idomeneo "74tom - 15 Mar 2022 - 12:57:11 - 1692 of 2344 Renalytix - AI Solutions Transforming The Management Of Kidney Disease - RENXIdomeneo, your posts remind me of a troll on a football forum pretending to support a team when they actually hate them. What you are saying is akin to going on a Spurs forum and posting that you think Harry Kane will leave on a free transfer or that he's going to retire at 28 to focus on other opportunities. It's complete nonsense to suggest RENX will run out of money, just like it was nonsense to say that raising $50m will double the share count or that shorters are here because they think RENX is like Theranos. Nobody who was invested here would be talking such rubbish, so please quit with the 'we' and go find something else to troll!" This was at £2.50 6 months after the 50 day and the 200 day had rolled over, the company had repeatedly claimed x was going to happen and it subsequently didn't. This guy went on to attack Paul Scott who has been a successful investor analysing several hundred companies a year for over 20 years and has unearthed many multi-baggers over that time. You get the same people who latch onto a stock and attack anybody else with a different view. As an investor you should be interested in looking at all the negatives of your investment, ideally this would be a place where that happens, but it never has. Where somebody would say " you are wrong for these reasons...". NB I didn't mention Theranos because it was a fraud and not relevant here, so he wrongly inferred that. |
Posted at 05/9/2023 06:46 by donald pond I can't help but feel we are getting close to the endgame here. Valuation is so low that if RENX can deliver a fraction of what the potential appears to be someone is going to buy them out soon. So the question is whether RENX can deliver, and whether the potential is what we think.I know they have FDA approval, but it doesn't feel as if there has been much take up since the CEO was talking about how revenues could jump from zero to hundreds of millions overnight, and IIRC that was in a podcast during covid lockdown. |
Posted at 13/7/2023 13:11 by mikemine1 Correct me if I'm wrong but RENX has reached practically all it's milestones now except breakeven point. FDA was the last major hurdle even though that didn't stop the company gaining multiple insurance acceptances and recognition of the validity of it's product without it. It even has a link up with a huge sales outlet that should propel the revenue stream quicker than RENX could do themselves.It's all good to me and we only need to have a bit more patience to see what happens in the next 6 months. I also note the increased interest which has pushed the share price to the £1.40 mark from sub £1.00. Lots of reasons to be happy IMHO and lots of potential upside for the share price I reckon. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
